About Inward rectifier potassium channel 16
Inward rectifier potassium channel 16 (KCNJ16) is a protein
from Homo sapiens identified by UniProt accession
Q9NPI9, 418 residues long.
MolForge cross-references it against 0 known binders and
171 disease associations.
Target properties
| Protein name | Inward rectifier potassium channel 16 |
| UniProt accession | Q9NPI9 |
| Gene | KCNJ16 |
| Organism | Homo sapiens |
| Length | 418 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (171)
Diseases linked to this target (Open Targets).
- hypokalemic tubulopathy and deafness · score 0.68
- body height · score 0.47
- appendicular lean mass · score 0.41
- cortical surface area measurement · score 0.38
- snoring measurement · score 0.35
- BMI-adjusted waist circumference · score 0.35
- birth weight · score 0.34
- sitting height measurement · score 0.34
- hereditary breast ovarian cancer syndrome · score 0.34
- PMM2-congenital disorder of glycosylation · score 0.34
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9NPI9-F1 | alphafold | PREDICTED | 78.13 | — |
Amino-acid sequence (418 residues)
MSYYGSSYHI INADAKYPGY PPEHIIAEKR RARRRLLHKD GSCNVYFKHI FGEWGSYVVD IFTTLVDTKW RHMFVIFSLS YILSWLIFGS VFWLIAFHHG DLLNDPDITP CVDNVHSFTG AFLFSLETQT TIGYGYRCVT EECSVAVLMV ILQSILSCII NTFIIGAALA KMATARKRAQ TIRFSYFALI GMRDGKLCLM WRIGDFRPNH VVEGTVRAQL LRYTEDSEGR MTMAFKDLKL VNDQIILVTP VTIVHEIDHE SPLYALDRKA VAKDNFEILV TFIYTGDSTG TSHQSRSSYV PREILWGHRF NDVLEVKRKY YKVNCLQFEG SVEVYAPFCS AKQLDWKDQQ LHIEKAPPVR ESCTSDTKAR RRSFSAVAIV SSCENPEETT TSATHEYRET PYQKALLTLN RISVESQM
Explore Inward rectifier potassium channel 16 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets